386 related articles for article (PubMed ID: 17460785)
1. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
[TBL] [Abstract][Full Text] [Related]
2. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
4. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Oldfield V; Plosker GL
Drugs; 2006; 66(9):1275-99. PubMed ID: 16827606
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.
Barragan P; Podzamczer D
Expert Opin Pharmacother; 2008 Sep; 9(13):2363-75. PubMed ID: 18710360
[TBL] [Abstract][Full Text] [Related]
6. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
Kaplan SS; Hicks CB
Expert Opin Pharmacother; 2005 Aug; 6(9):1573-85. PubMed ID: 16086645
[TBL] [Abstract][Full Text] [Related]
7. Lopinavir.
Hurst M; Faulds D
Drugs; 2000 Dec; 60(6):1371-9; discussion 1380-1. PubMed ID: 11152017
[TBL] [Abstract][Full Text] [Related]
8. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
[TBL] [Abstract][Full Text] [Related]
9. Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.
Croxtall JD; Perry CM
Drugs; 2010 Oct; 70(14):1885-915. PubMed ID: 20836579
[TBL] [Abstract][Full Text] [Related]
10. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.
Kaplan SS; Hicks CB
J Antimicrob Chemother; 2005 Aug; 56(2):273-6. PubMed ID: 15994247
[TBL] [Abstract][Full Text] [Related]
11. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
[TBL] [Abstract][Full Text] [Related]
12. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
[TBL] [Abstract][Full Text] [Related]
13. The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy.
Overton ET; Tschampa JM; Klebert M; Royal M; Rodriguez M; Spitz T; Kim G; Mondy KE; Acosta EP
J Clin Pharmacol; 2010 Sep; 50(9):1050-5. PubMed ID: 20147613
[No Abstract] [Full Text] [Related]
14. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
15. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
16. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.
Tan D; Walmsley S
Expert Rev Anti Infect Ther; 2007 Feb; 5(1):13-28. PubMed ID: 17266450
[TBL] [Abstract][Full Text] [Related]
17. Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice.
Romano L; Peduzzi C; Venturi G; Di Pietro M; Carli T; Corsi P; Gonnelli A; Valensin PE; Zazzi M
J Acquir Immune Defic Syndr; 2002 Aug; 30(5):533-5. PubMed ID: 12154345
[No Abstract] [Full Text] [Related]
18. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
Podzamczer D; King MS; Klein CE; Flexner C; Katlama C; Havlir DV; Letendre SL; Eron JJ; Brun SC; Bernstein B
HIV Clin Trials; 2007; 8(4):193-204. PubMed ID: 17720659
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Madruga JV; Berger D; McMurchie M; Suter F; Banhegyi D; Ruxrungtham K; Norris D; Lefebvre E; de Béthune MP; Tomaka F; De Pauw M; Vangeneugden T; Spinosa-Guzman S;
Lancet; 2007 Jul; 370(9581):49-58. PubMed ID: 17617272
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
